戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 % [63.1-88.5] vs 82.9% [67.8-95.9], p=0.001) bronchodilation.
2 VC of 10% of predicted value or greater with bronchodilation.
3 al epithelial cells and prostanoid-dependent bronchodilation.
4  pressure fluctuations, can generate greater bronchodilation.
5 ransmural pressures can lead to only limited bronchodilation.
6 low limitation at day 0 was reversible after bronchodilation.
7 ective airway reflexes, ciliary beating, and bronchodilation.
8 e exacerbation and provided modest sustained bronchodilation.
9 ay smooth muscle (ASM) relaxation leading to bronchodilation.
10 mportant than distal alveolar deposition for bronchodilation.
11 position for the larger particles, with less bronchodilation.
12  AUC values when compared to spirometry with bronchodilation.
13 PGE(2) limits lung inflammation and promotes bronchodilation.
14 thway plays a significant role in human lung bronchodilation.
15 fect of counteracting B(2)AR agonist-induced bronchodilation.
16 e or Syk and p38 MAPK did not cause additive bronchodilation.
17 th a mean FEV(1) of 1.32+/-0.44 liters after bronchodilation (48% of predicted value), we randomly as
18         Therefore, the mechanism for reduced bronchodilation after DIs in subjects with mild asthma c
19                                 There was no bronchodilation after nine doses of the 5-lipoxygenase i
20                                              Bronchodilation after salbutamol was equal to or greater
21 ansient decreases in Pa(O(2)) levels despite bronchodilation, an effect that has been attributed to t
22 me in 1 second (FEV(1)) of 70% or less after bronchodilation and a ratio of FEV(1) to forced vital ca
23 not significantly different before and after bronchodilation and are different in patients with COPD
24                         From these outcomes, bronchodilation and bronchoprotection indices were const
25  the trial (ranging from 87 to 103 ml before bronchodilation and from 47 to 65 ml after bronchodilati
26 CS plus LABA provided modest improvements in bronchodilation and increased the time to first severe e
27 es airway smooth muscle (ASM) relaxation and bronchodilation, and beta(2)AR agonists (beta-agonists)
28 omisation table for an assessment of safety, bronchodilation, and bronchoprotection.
29 fects of pathologic status, session, reader, bronchodilation, and CT examination were assessed by usi
30 ollection, skin prick tests, spirometry with bronchodilation, and exhaled nitric oxide.
31 s mediated by the EP2 receptor, unrelated to bronchodilation, and increased with time of exposure.
32 c inflammation in asthma may impede NO-based bronchodilation, and reveal that pharmacologic sGC agoni
33 ep inspiration-induced bronchoprotection and bronchodilation are impaired in asthma.
34 These results indicate the potential of dual bronchodilation as a treatment option for patients with
35 ) given twice daily cause the same degree of bronchodilation as tiotropium bromide given once daily.
36 e bronchodilation and from 47 to 65 ml after bronchodilation), as compared with the placebo group (P<
37 onducted with the use of qCT images (maximal bronchodilation at total lung capacity [TLC], or inspira
38  decline in the mean FEV(1) before and after bronchodilation beginning on day 30.
39 he B(2)-adrenergic receptor (B(2)AR) induces bronchodilation by activating the enzyme adenylyl cyclas
40 nergic pulmonary function and contributes to bronchodilation by NO.
41 acholine responsiveness, deep-breath-induced bronchodilation (DeltaR(rs) ) and bronchoscopy with endo
42 th decreased and increased FENO levels after bronchodilation, depending on the site of airway obstruc
43  that pharmacologic sGC agonists can achieve bronchodilation despite this loss.
44 here were no significant session, reader, or bronchodilation effects on WT in third-generation airway
45  develop airway hyperreactivity and impaired bronchodilation following supplemental O(2) (hyperoxia)
46  mucus production from submucosal glands and bronchodilation have been proposed.
47 onse to beta2 -agonists, as well as impaired bronchodilation in a mouse lung slices.
48 -agonists) promote - with limited efficacy - bronchodilation in asthma.
49    We recently described rapid TLR7-mediated bronchodilation in guinea pigs.
50 struction in all four groups, albeit percent bronchodilation in healthy subjects was somewhat stronge
51 nists BAY 41-2272 and BAY 60-2770, triggered bronchodilation in normal human lung slices and in mouse
52                        RPL554 produced rapid bronchodilation in patients with asthma with an FEV1 inc
53 airway smooth muscle (ASM) causes a stronger bronchodilation in vitro and in vivo than beta2 agonists
54 n is associated with bronchoconstriction and bronchodilation in vivo.
55     Up to day 5 of hospital stay, FEV1 after bronchodilation increased by 90 mL daily (50.8-129.2) an
56                                   FEV1 after bronchodilation increased more rapidly and to a greater
57 on was equal to their ability to prevent it (bronchodilation index [BDI] versus bronchoprotection ind
58                                     Although bronchodilation is a cornerstone of treatment, current b
59                                However, this bronchodilation is dysfunctional in asthma due to high N
60 eroids and maximal pharmacologically induced bronchodilation is the main cause of treatment failure.
61                               In addition to bronchodilation, LAMA also exert anti-inflammatory and a
62                                Thus, besides bronchodilation, LAMA might provide additional therapeut
63 nsive characterization of salmeterol-induced bronchodilation, little is known about the molecular act
64 Associations of these trajectories with post-bronchodilation lung function parameters at 15 years and
65                                TLR7-mediated bronchodilation may be a new therapeutic strategy in ast
66 se (COPD) is a condition in which continuous bronchodilation may have clinical advantages.
67 already been induced by MCh, following a DI, bronchodilation occurred in the healthy subjects but fur
68 e of less than -1.64 or a change in FVC with bronchodilation of >=10% predicted.
69 d bronchoconstriction, and actively promoted bronchodilation of airways ex vivo.
70  us to hypothesize that the maximum possible bronchodilation of an airway depends on its static compl
71 relaxation of contracted human ASM cells and bronchodilation of contracted airways.
72 le blocking activated L-type VDCCs to induce bronchodilation of contracted ASM.
73 ls of peroxidases and H(2)O(2), NO-dependent bronchodilation of preconstricted tracheal rings was rev
74 sessed during induced bronchoconstriction or bronchodilation or during changes in airway resistance w
75  potentially provide additive or synergistic bronchodilation over either inhaled antimuscarinic or be
76 bromide), in COPD is encouraging because the bronchodilation produced is of a magnitude greater than
77               Measurements and Main Results: Bronchodilation resulted in higher predicted medians and
78 eated group: percentage predicted FEV1 after bronchodilation rose from 25.7% (95% CI 21.0-30.4) to 32
79 e dissociation between bronchoprotection and bronchodilation suggests that the two effects involve di
80 rental interviews, clinical examinations and bronchodilation test of 138 of those children at 11-13 y
81 ) were more efficacious and achieved greater bronchodilation than 200 microg MDI albuterol (deltaFEV1
82   Alpha-adrenergic blockade may promote mild bronchodilation that offsets non-selective beta blockade
83      T2 asthma usually responds to classical bronchodilation therapy and corticosteroid treatment.
84 s of resistance) after exercise challenge or bronchodilation was present in nine (12%) children.
85  decline in the mean FEV(1) before and after bronchodilation were not significant.
86 (R)-enantiomer of racemic albuterol produces bronchodilation, whereas the (S)-enantiomer may increase
87  impaired subsequent beta(2)-agonist-induced bronchodilation, which occurred independently of changes
88 to understand the mechanisms underlying this bronchodilation, which remain ill-defined.
89                              RPL554 produced bronchodilation with a mean maximum FEV1 increase of 17.
90          Rationale: In the CLAIM study, dual bronchodilation with indacaterol/glycopyrronium (IND/GLY
91  expiratory volume in 1 second (FEV1) before bronchodilation, with a difference of 0.10 liters (P=0.0